Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seltorexant - Janssen Research & Development/Minerva Neurosciences

Next Previous
X
Search
Drug Profile

Seltorexant - Janssen Research & Development/Minerva Neurosciences

Alternative Names: JNJ-42847922; JNJ-7922; MIN-202

Latest Information Update: 23 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Minerva Neurosciences
  • Class Antidepressants; Fluorinated hydrocarbons; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Phase II Alzheimer's disease; Insomnia
  • No development reported Sleep apnoea syndrome

Most Recent Events

  • 25 Jul 2024 Janssen Research & Development initiates a phase III trial for Major depressive disorder (Adjunctive treatment, Treatment-experienced) in USA (PO) (NCT06559306) ( EudraCT2023-509070-36-00)
  • 29 May 2024 Efficacy and adverse event data from a phase III trial in Major depressive disorder released by Johnson & Johnson
  • 28 May 2024 No recent reports of development identified for phase-I development in Major depressive disorder(Adjunctive treatment) in Germany (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top